| Name | Title | Contact Details |
|---|---|---|
Elena Polansky |
Vice President Global Sourcing and Procurement | Profile |
Erin Burkhart |
Group Vice President and Chief Accounting Officer | Profile |
Humaira Serajuddin |
Senior Vice President and Chief Marketing Officer | Profile |
Trevor Thomas |
Associate Director of Threat and Incident Management | Profile |
Parker Stock |
Associate Director, Technical Accounting and Policy | Profile |
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
Verdezyne is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.
Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine`s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.